Aptinyx: Surges on positive results from PTSD therapy study

Aptinyx

19/10/2020 22:37

** Drug developer's shares  APTX.O  jump 75.96% to $6.44
after hours
    ** Co reports positive results from a mid-stage study of its
treatment for patients with post-traumatic stress disorder
(PTSD)  urn:newsml:reuters.com:*:nBwc2lh2Pa
    ** Says the treatment, NYX-783, showed statistically
significant and clinically meaningful efficacy results in a test
on 153 patients 
    ** Co expects to initiate a pivotal study in 2021
    ** U.S. FDA granted company a fast-track tag for the
development of NYX-783 
    ** APTX stock up ~7% YTD

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 80 6749 6132;))